Anti-Coagulants - Europe

Europe

The Anti-Coagulants market in Europe is expected to experience significant growth in the coming years.
It is projected that by 2024, the revenue will reach a staggering €5.43bn.
This growth is expected to continue at an annual growth rate of 7.60% from 2024 to 2029.
As a result, the market volume is estimated to reach €7.83bn by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue in the Anti-Coagulants market.
It is projected that by 2024, the revenue United States will reach an impressive €15,520.00m.
In Europe, Germany is leading the way in the development and adoption of novel anti-coagulants for the treatment of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

Anti-Coagulants, also known as blood thinners, are medications that help prevent blood clots. The market for Anti-Coagulants in Europe has been growing steadily in recent years.

Customer preferences: Patients prefer Anti-Coagulants over other treatments due to their effectiveness in preventing blood clots, which can lead to serious health problems such as stroke and heart attack. Additionally, the convenience of taking one pill a day has increased patient compliance.

Trends in the market: In Europe, the market for Anti-Coagulants is being driven by the increasing incidence of cardiovascular diseases, which is leading to a higher demand for blood thinners. The market is also being shaped by the introduction of new oral Anti-Coagulants that are more effective and have fewer side effects than traditional treatments. These new drugs are gaining popularity among patients and are expected to continue to drive growth in the market.

Local special circumstances: Germany has the largest market for Anti-Coagulants in Europe due to its high prevalence of cardiovascular diseases and an aging population. The UK and France also have significant markets for Anti-Coagulants, driven by similar factors. However, the market in Italy and Spain is relatively small due to lower incidence rates of cardiovascular diseases.

Underlying macroeconomic factors: The growing prevalence of cardiovascular diseases in Europe is being driven by factors such as an aging population, sedentary lifestyles, and unhealthy diets. Additionally, advancements in medical technology and healthcare infrastructure are improving the detection and treatment of cardiovascular diseases, leading to increased demand for Anti-Coagulants. The rise of healthcare spending and government initiatives to improve healthcare access and affordability are also contributing to the growth of the Anti-Coagulants market in Europe.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.